FOR US HEALTHCARE PROFESSIONALS ONLY
In a post hoc analysis, INVEGA SUSTENNA® demonstrated symptom control for patients earlier in their course of disease1*
reduced risk of relapse vs oral antipsychotics in adults treated within the first 3 to 5 years after diagnosis1*
reduced risk of relapse vs a group of oral antipsychotics regardless of time after diagnosis (HR 0.69; 95% CI=0.56-0.86, P<0.001)1*
- Risk of relapse was reduced for patients receiving INVEGA SUSTENNA® vs a group of oral antipsychotics by1:
- 33% in the 0- to 3-year group (HR 0.67; 95% CI 0.44-1.00, P=0.050)
- 43% in the >3- to 5-year group (HR 0.57; 95% CI 0.35-0.93, P=0.025)
- 26% in the >5-year group (HR 0.74; 95% CI 0.55-1.00, P=0.049)
- Patients from this post hoc analysis were adults from the PRIDE and PROSIPAL studies and were required to be experiencing schizophrenia symptoms (per DSM-IV®) or confirmed diagnosis of schizophrenia. A regression analysis of survival data based on a Cox proportional hazards model was used and analyzed factors including age, study, duration of illness, treatment group, and interaction between duration of illness and treatment group1
DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; PRIDE=Paliperidone Palmitate Research in Demonstrating Effectiveness; PROSIPAL=Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate.
*Results from a patient-level, post hoc analysis evaluating the risk of relapse in adults with schizophrenia overall by varying duration of illness comparing INVEGA SUSTENNA® vs a group of oral antipsychotics. 0-3 years: INVEGA SUSTENNA®, n=253, oral antipsychotic, n=263; >3-5 years: INVEGA SUSTENNA®, n=138, oral antipsychotic, n=134; >5 years: INVEGA SUSTENNA®, n=187, oral antipsychotic, n=182.1
Study design & limitations
Methods1
- Patients are from the PRIDE (NCT01157351) and PROSIPAL (NCT01081769) studies. Both studies have similar but not identical inclusion and exclusion criteria and definitions for relapse or treatment failure (TF)
- TF (relapse) was defined differently across studies but included relapses due to psychiatric hospitalizations, arrest, or incarceration, suicidal or homicidal ideation or behavior, discontinuation due to inadequate efficacy and/or safety or tolerability, treatment supplementation due to inadequate efficacy, and worsening of symptoms (based on the Positive and Negative Syndrome Scale or the Clinical Global Impressions Scale)
- Kaplan-Meier method was used to assess the cumulative distribution functions of time to TF or relapse
- Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were documented
Study limitations1
- Patients in the study may not be representative of the real-world population with recent-onset schizophrenia due to specific inclusion/exclusion criteria
- The studies used in this post hoc analysis differed in design, including observation time, inclusion/exclusion criteria, and the oral antipsychotics used were not exactly the same
PRIDE=Paliperidone Palmitate Research in Demonstrating Effectiveness; PROSIPAL=Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate.
Reference: 1. Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: an integrated patient-level meta analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227-2235.